WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of ...

today announced that it has dosed the first participant in its EMERALD Phase 2 clinical study of NGM120, a GFRAL antagonist designed to block GDF15 activity, for the treatment of hyperemesis ...